AstraZeneca’s anti-diabetic drug receives CDSCO approval for patients with chronic kidney disease and heart failure | The Financial Express

AstraZeneca’s anti-diabetic drug receives CDSCO approval for patients with chronic kidney disease and heart failure

Chronic kidney disease (CKD) is one of the leading causes of hospitalization globally and in India, representing a significant clinical and economic burden.

AstraZeneca’s anti-diabetic drug receives CDSCO approval for patients with chronic kidney disease and heart failure
AstraZeneca’s Dapagliflozin is an oral anti-diabetes drug which has shown increasing benefits in not only preventing heart failure but also in managing chronic kidney disease and Heart failure, the company claimed. (File)

AstraZeneca India, a science-led biopharmaceutical company on Tuesday announced that the company has received the Central Drugs Standard Control Organization’s (CDCSCO) approval for their anti-diabetic drug Dapagliflozin in the treatment of adults with chronic kidney disease (CKD).

According to the pharma major, Dapagliflozin is the first and only anti-diabetic drug approved to significantly reduce the risk of sustained eGFR (estimated Glomerular Filtration Rate), cardiovascular deaths and hospitalizations due to heart failure in adults with progressive chronic kidney disease. This approval is applicable for both diabetic and non-diabetic CKD patients.

“The approval is based on the consistent results from the DAPA-CKD study, where the indication has now been recommended in adults with Chronic Kidney Disease, up to an eGFR greater than or equal to 25 ml per min per 1.73 m2. Below this, the initiation is currently not recommended, however patients may continue with their daily dose of 10mg orally to reduce the risk of eGFR decline, End Stage Kidney Disease (ESKD), cardiovascular deaths and heart failures. Earlier only up to CKD stage 3 patients could be initiated Dapagliflozin but with this approval physicians can initiate Dapagliflozin for a subset of CKD stage 4,” the company said in a statement.

Chronic kidney disease (CKD) is one of the leading causes of hospitalization globally and in India, representing a significant clinical and economic burden. CKD is progressive disease and continues to be the major cause of morbidity and mortality, with adverse outcomes of kidney failure and premature death.

Studies show that the prevalence of CKD in India is estimated to be 17.2 percent and nearly 10 Million patients may be on stage 4 CKD.

AstraZeneca’s Dapagliflozin is an oral anti-diabetes drug which has shown increasing benefits in not only preventing heart failure but also in managing chronic kidney disease and Heart failure with reduced ejection fraction irrespective of Diabetes status, the company claims.

“The timely approval of Dapagliflozin from the CDCSCO committee with the additional indication is a huge boost for nephrologists across the country towards the management of progressive Chronic Kidney Disease. At AstraZeneca, we are committed to constantly push the boundaries of science and technology to address the unmet need of heart failures and CKDs globally. Today, there is a paradigm shift in the usage of leading diabetic drugs for a wider scope and we see huge potential for this segment. The approval will provide the clinical community with a potential therapeutic option to arrest the progression of CKDs and address heart failures at an early stage,” Dr. Anil Kukreja, Vice President – Medical Affairs and Regulatory, AstraZeneca India said in a statement.

ALSO READ | AstraZeneca’s breast cancer drug Enhertu shows promising results in patients

Get live Share Market updates and latest India News and business news on Financial Express. Download Financial Express App for latest business news.

First published on: 29-11-2022 at 13:16 IST